Prothena Corp Public (PRTA) EBT Margin (2013 - 2026)
Prothena Corp Public (PRTA) recorded quarterly EBT Margin of 64.06% in Q1 2026, up 100.06% quarter-over-quarter from 102757.14% in Q4 2025, and up 223425.0% on a YoY basis from N/an in Q1 2025.
Prothena Corp Public (PRTA) EBT Margin (2013 - 2026) Analysis & Trends
Prothena Corp Public's EBT Margin history runs 14 years deep, the most recent figure standing at 64.06% for Q1 2026.
- In Q1 2026, EBT Margin rose 223425.0% year-over-year to 64.06%; the TTM figure through Mar 2026 stood at 184.21% (down 10022.0% YoY), while the FY2025 annual figure was 2073.82%, down 197843.0% from the prior year.
- EBT Margin was 64.06% for Q1 2026 at Prothena Corp Public, up from 102757.14% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 64.06% in Q1 2026 to a low of 148880.0% in Q1 2024.
- Historically, EBT Margin has averaged 17754.92% across 5 years, with a median of 2294.88% in 2023.
- The sharpest annual moves came in 2024 and 2025: EBT Margin tumbled 14658512 bps in 2024, then soared 14670981 bps in 2025.
- A 5-year view of EBT Margin shows it stood at 6.7% in 2022, then sank by 333628 bps to 22347.47% in 2023, then soared by 87 bps to 2802.68% in 2024, then plunged by 3566 bps to 102757.14% in 2025, then jumped by 100 bps to 64.06% in 2026.
- The last three EBT Margin figures came in at 64.06% (Q1 2026), 102757.14% (Q4 2025), and 1528.45% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 6.40% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 41.95% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Prothena Corp Public | 479.08 Mn | 149.61 Mn | - | 64.06% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.06% |
| Dec 31, 2025 | -102,757.14% |
| Sep 30, 2025 | -1,528.45% |
| Jun 30, 2025 | -1,831.79% |
| Mar 31, 2025 | -2,170.19% |
| Dec 31, 2024 | -2,802.68% |
| Sep 30, 2024 | -6,168.66% |
| Jun 30, 2024 | 49.12% |
| Mar 31, 2024 | -148,880.00% |
| Dec 31, 2023 | -22,347.47% |
| Sep 30, 2023 | 22.17% |
| Jun 30, 2023 | -1,465.56% |
| Mar 31, 2023 | -2,294.88% |
| Dec 31, 2022 | 6.70% |
| Sep 30, 2022 | -3,191.63% |
| Jun 30, 2022 | -3,244.82% |
| Mar 31, 2022 | -3,292.37% |
| Dec 31, 2021 | -2,823.89% |
| Sep 30, 2021 | 78.46% |
| Jun 30, 2021 | 46.44% |